GLP-1s represent a systemic approach by flooding the body with pharmacologic signals focused on weight loss. Scientists are now working on alternatives: technologies that zero in on the specific anatomic regions where the patient has adipose deposits. They’re leveraging nanotechnology to deliver therapeutics directly into adipose tissue in what eventually could provide significantly more precise treatment options to complement or even bypass conventional therapies.

This targeted approach may hold the promise of overcoming the limitations of current therapies, such as poor adherence to lifestyle interventions, the invasive nature of bariatric surgery, and the lack of specificity of current obesity medications, which can lead to off-target effects and reduced therapeutic efficiency, wrote Sheetal Sharma, PhD, of the Centre of Excellence in Nanotechnology in the Research and Development Cell at Lovely Professional University, Phagwara, India, in a recent review in Obesity Medicine.

The foundation of targeted nanomedicine rests on understanding obesity not merely as a state of caloric excess but as a complex, multifactorial metabolic disorder. In obesity, adipose tissue undergoes substantial changes, such as the proliferation and expansion of adipocytes, hypoxia, fibrosis, and infiltration of immune cells, Sharma noted. These changes contribute to chronic low-grade inflammation and set the stage for several comorbid conditions, including type 2 diabetes, cardiovascular disease, some cancers, and metabolic dysfunction-associated steatotic liver disease, she added.

In this nascent field, scientists are developing nanomedicines, the application of nanotechnology — meaning working with materials on an atomic and molecular scale, typically 1 to 100 nm — to prevent, diagnose, and treat disease. Their aim is to modify the metabolic pathways that drive energy storage, adipocyte growth, inflammation, and insulin resistance. This work involves determining which markers would direct nanocarriers to the desired targets in adipose tissue and engineering those nanoparticles to be able to deliver their therapeutic payload.

Several nanomedicines are being studied in preclinical research, often involving mice, and at least one has advanced to clinical trials, noted Lingling Wang and colleagues in the Department of Pharmacy at West China Hospital, Sichuan University, Chengdu, China, in a recent review.

The Science of Precision Delivery

To identify the appropriate targets for therapeutic-loaded nanoparticles, scientists first examined the distinct biology of adipose tissue, including the nature of white, brown, and beige adipocytes, Sharma wrote. While white adipose tissue primarily stores excess energy and drives proinflammatory cascades when overwhelmed, brown and beige adipocytes specialize in thermogenesis and energy expenditure.

Armed with that knowledge, scientists are developing active targeting strategies in which nanocarriers home in on adipocytes and on the endothelial cells, macrophages, and stromal cells in adipose tissue, Wang and colleagues wrote. They’re also using passive targeting strategies in which the nanoparticles zero in on specific microenvironmental cues within inflamed or hypoxic fat tissue, such as local pH drops or enzymatic activity.

These nanocarriers must overcome challenges posed by pharmacokinetics to deliver their therapeutic agents — whether synthetic small molecules, genetic modulators, or natural bioactive compounds. Rapid degradation, poor bioavailability, and systemic clearance have historically prevented promising molecules from reaching therapeutic concentrations in diseased fat deposits.

To tackle these challenges, scientists are developing diverse carrier platforms. Lipid-based systems utilize liposomes, solid lipid nanoparticles, and nanostructured lipid carriers to encapsulate hydrophobic drugs for delivery to adipose tissue, Wang and colleagues noted. Polymeric nanoparticles employ biocompatible matrices for sustained, controlled drug release, while inorganic and biomimetic nanomaterials leverage unique structural properties or cell-derived membrane coatings to evade immune-system clearance. Stimuli-responsive smart carriers are those engineered to release their payloads only when triggered by specific microenvironmental cues.

By attaching specific peptides, antibodies, or glycans to the surface of nanoparticles, researchers can direct payloads directly to the intended target. Once there, the therapeutic agent can do its work, for example, promoting the browning of adipose tissue to boost energy expenditure or blocking inflammatory pathways to reduce glucose intolerance and insulin resistance, Wang and colleagues wrote.

Nano-enabled platforms open the door to therapies that target multiple dysfunctions in adipose tissue, for example, promoting both lipolysis and inflammation relief, they added.

However, translating these bench-level breakthroughs into human clinical practice requires navigating significant hurdles. Researchers must address manufacturing scalability, minimize potential immunogenicity and carrier accumulation with repeated exposure, and satisfy rigorous regulatory requirements.

Still, supporters of this approach say that integrating precision nanomedicine into obesity management would ultimately represent a vital evolutionary step, moving metabolic care away from blanket systemic approaches toward precise, tissue-specific restoration of metabolic health.

The Clinical Blind Spot: Beyond the Scale and Systemic Sledgehammers

Sean Arora, MD, obesity expert and co-founder and CEO of Arora Health & Aesthetics, Seattle, Washington, told Medscape Medical News, it’s important that the obesity medicine field continue incorporating the whole-body point of view.

“We have made the number on the scale the primary endpoint for obesity treatment, but weight is only one part of the picture. A patient might lose only 5 pounds while experiencing meaningful improvements in insulin sensitivity, blood sugar, inflammation, liver health, or cardiovascular risk.... The goal should not simply be to make patients smaller. It should be to make them healthier.”

Arora said that when a patient experiences profound metabolic shifts independent of massive weight loss, the limitation of our traditional metrics becomes obvious, forcing specialists to look deeper at the micro-level pathology of the tissue itself.

Regarding the nanotechnology itself, he said, “I believe combination therapy is where this category may ultimately become most useful. GLP-1 medications have changed metabolic medicine, but they do not address every pathway involved in obesity and metabolic dysfunction. Patients also respond very differently.”

Arora urged caution regarding these results, however. “That does not mean we should make promises before the data exists. However, we should be actively studying these combinations and, where legally and clinically appropriate, developing responsible frameworks for evaluating emerging therapies.”

Deconstructing Adipose Dysfunction 

The core pathology of obesity is tissue overload, rather than simple mass accumulation, said Evan Nadler, MD, obesity expert and founder of ProCare Consultants and ProCare TeleHealth, who has an extensive background in research involving adipocyte-derived exosomes and silencing RNAs. So to target metabolic disease at its root, specialists must grapple with the structural reality of fat mass.

“Fat cells don’t cause obesity. The way it works is that when the fat cells have exceeded their capacity to store excess energy, they become dysfunctional and then send signals throughout the body causing end organs to malfunction,” he told Medscape Medical News. “The most promising approaches at this point use mRNA. I believe there are early-stage human trials already underway using this approach, but it takes about 10 years for any therapy to go from early human trials to clinical use.”

The ubiquity of fat throughout the human body could make intervening at the cellular level problematic, Nadler said.

“While synthetic nanoparticles may specifically target adipose tissue, there is adipose tissue throughout the human body, so a strategy to address visceral adipose, as opposed to subcutaneous adipose, would be needed,” he said.

A trial testing the safety and tolerability of an experimental injectable nanomedicine, called STP705, which is composed of two small interfering RNAs that reduce the expression of transforming growth factor beta 1 and COX-2, in adults undergoing abdominoplasty has been completed. It involved eight adult women who received three rounds of treatment with seven injections of STP705 or placebo administered 28 days apart.

Researchers found no clinically significant changes in clinical labs, vital signs, or ECGs, and local skin reactions were low throughout the study. There were three moderate adverse events deemed likely to be related to STP705 injection, but none required intervention and all resolved without dose modification. Histology of tissue samples collected from abdominoplasty, conducted 28 days after the final injection, revealed marginally dose-dependent tissue response with adipocyte destruction and fat remodeling.

Weighing the Promise of Nanomedicine Against Clinical Reality

Alexander Zuriarrain, MD, an obesity medicine specialist and plastic surgeon at Zuri Plastic Surgery in South Miami, Florida, said the theoretical promise of targeted delivery could be a paradigm shift.

“On paper it works: Wrap the drug in a tiny particle tagged to home in on fat, and you keep it concentrated there instead of hitting the whole body. This should spare the heart from the overstimulation these drugs can otherwise cause.”

At the same time, Zuriarrain said enthusiasm should be tempered with a realistic view of the translational gap.

“The carrier itself can trigger immune reactions, it’s hard to manufacture at scale, and the long-term safety in humans simply isn’t known yet,” he said.

Despite those hurdles, some experts view the clinical incentive to solve this puzzle as undeniable, particularly when evaluating how regional fat distribution drives disease. Zurriarain referenced a landmark 10-year follow-up study published in Circulation, led by researchers from Ben-Gurion University of the Negev, Harvard T.H. Chan School of Public Health, and international collaborators. This study noted that during the 18-month CENTRAL and DIRECT-PLUS randomized controlled trials, participants achieved considerable reductions in abdominal and ectopic fat. Lead author Hadar Klein, RD, MSc, of the Health & Nutrition Innovative International Research Center at the Ben-Gurion University of the Negev, Beer-Sheva, Israel, evaluated long-term MRI data from participants who completed these major lifestyle and dietary clinical trials to see what happened to their health 5-10 years after the initial intervention ended.

Zuriarrain said that even after participants regained weight after the trials, keeping visceral fat down still lined up with better health.

“Every 10% drop in it equals roughly 28% lower odds of developing type 2 diabetes,” he said. “Where the fat sits and how healthy it is may matter as much as how much of it there is.”

Arora said a future where adipose-targeted therapies act as sophisticated complements to foundational medications is his vision.

“An adipose-targeted therapy could potentially complement a GLP-1 medication by working through a different mechanism,” he said. “It could help patients who have reached a plateau, improving metabolic markers beyond weight loss, or eventually allowing some patients to use lower GLP-1 doses.”

Arora, Nadler, and Zuriarrain reported having no disclosures.